adenine has been researched along with Parkinsonian Disorders in 7 studies
Parkinsonian Disorders: A group of disorders which feature impaired motor control characterized by bradykinesia, MUSCLE RIGIDITY; TREMOR; and postural instability. Parkinsonian diseases are generally divided into primary parkinsonism (see PARKINSON DISEASE), secondary parkinsonism (see PARKINSON DISEASE, SECONDARY) and inherited forms. These conditions are associated with dysfunction of dopaminergic or closely related motor integration neuronal pathways in the BASAL GANGLIA.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (14.29) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (14.29) | 29.6817 |
| 2010's | 4 (57.14) | 24.3611 |
| 2020's | 1 (14.29) | 2.80 |
| Authors | Studies |
|---|---|
| Guo, Q | 1 |
| Wang, B | 1 |
| Wang, X | 1 |
| Smith, WW | 1 |
| Zhu, Y | 1 |
| Liu, Z | 1 |
| Mercado, G | 1 |
| Castillo, V | 1 |
| Soto, P | 1 |
| López, N | 1 |
| Axten, JM | 1 |
| Sardi, SP | 1 |
| Hoozemans, JJM | 1 |
| Hetz, C | 1 |
| Stasi, MA | 1 |
| Minetti, P | 1 |
| Lombardo, K | 1 |
| Riccioni, T | 1 |
| Caprioli, A | 1 |
| Vertechy, M | 1 |
| Di Serio, S | 1 |
| Pace, S | 1 |
| Borsini, F | 2 |
| Fuzzati-Armentero, MT | 1 |
| Cerri, S | 1 |
| Levandis, G | 1 |
| Ambrosi, G | 1 |
| Montepeloso, E | 1 |
| Antoninetti, G | 1 |
| Blandini, F | 1 |
| Baqi, Y | 1 |
| Müller, CE | 1 |
| Volpini, R | 1 |
| Costa, G | 1 |
| Simola, N | 1 |
| Pinna, A | 1 |
| Frau, L | 1 |
| Wardas, J | 1 |
| Khairnar, AS | 1 |
| Schintu, N | 1 |
| Morelli, M | 1 |
| GOMIRATO, G | 1 |
| HYDEN, H | 1 |
| Rose, S | 1 |
| Ramsay Croft, N | 1 |
| Jenner, P | 1 |
7 other studies available for adenine and Parkinsonian Disorders
| Article | Year |
|---|---|
Activation of Nrf2 in Astrocytes Suppressed PD-Like Phenotypes via Antioxidant and Autophagy Pathways in Rat and Drosophila Models.
Topics: Adenine; Animals; Animals, Genetically Modified; Antioxidants; Antiparkinson Agents; Astrocytes; Aut | 2021 |
Targeting PERK signaling with the small molecule GSK2606414 prevents neurodegeneration in a model of Parkinson's disease.
Topics: Adenine; Animals; Disease Models, Animal; eIF-2 Kinase; Female; Humans; Indoles; Male; Mice; Mice, I | 2018 |
Animal models of Parkinson׳s disease: Effects of two adenosine A2A receptor antagonists ST4206 and ST3932, metabolites of 2-n-Butyl-9-methyl-8-[1,2,3]triazol-2-yl-9H-purin-6-ylamine (ST1535).
Topics: Adenine; Adenosine A2 Receptor Antagonists; Administration, Oral; Animals; Antiparkinson Agents; Bas | 2015 |
Dual target strategy: combining distinct non-dopaminergic treatments reduces neuronal cell loss and synergistically modulates L-DOPA-induced rotational behavior in a rodent model of Parkinson's disease.
Topics: Adenine; Animals; Drug Delivery Systems; Drug Synergism; Levodopa; Male; Neurons; Neuroprotective Ag | 2015 |
Neuroprotective and anti-inflammatory effects of the adenosine A(2A) receptor antagonist ST1535 in a MPTP mouse model of Parkinson's disease.
Topics: Adenine; Adenosine A2 Receptor Antagonists; Animals; Anti-Inflammatory Agents; Brain; Immunohistoche | 2011 |
A BIOCHEMICAL GLIA ERROR IN THE PARKINSON DISEASE.
Topics: Adenine; Cytosine; Globus Pallidus; Guanine; Neurochemistry; Neuroglia; Neurons; Nucleic Acids; Park | 1963 |
The novel adenosine A2a antagonist ST1535 potentiates the effects of a threshold dose of l-dopa in unilaterally 6-OHDA-lesioned rats.
Topics: Adenine; Adenosine; Adenosine A2 Receptor Antagonists; Animals; Brain; Disease Models, Animal; Dopam | 2007 |